Trump administration advances plan for peptide drugs favored by RFK Jr.

HHS submitted an interim policy to the White House that could let specialty pharmacies temporarily compound certain peptides, including BPC-157, through FDA enforcement discretion; the proposal is not final and the filing gives few details. FDA staff have said the peptides have not been studied enough to establish safety and effectiveness, and the agency has cited risks including contamination, allergic reactions and tumor growth. Hims & Hers and Noom have said they plan to offer peptides if access is eased, while analysts estimate the market could reach $2 billion to $3 billion.

Analysis

The key distinction for HIMS is regulatory permission to exercise discretion, not FDA validation of safety or effectiveness. If finalized, the policy could create a new customer-acquisition and retention hook, but conversion into durable revenue depends on which compounds are covered, launch timing, pharmacy capacity, and whether customers repeat after initial use. None is established by the filing. Hims & Hers and Noom may gain an advantage over providers that do not offer these products; specialty compounders could also benefit. Conversely, a severe adverse event or misleading promotion could trigger scrutiny across the category, raising compliance costs and damaging trust beyond the seller directly involved. This would be a regulatory and reputational spillover, not evidence that HIMS itself has experienced an incident.

Near term, White House review and the eventual policy text are the catalysts: scope, duration, sourcing and oversight matter more than favorable political messaging. Over 1–3 months, watch whether HIMS discloses an actual offering, fulfillment partner, safeguards and customer uptake. Over 6–18 months, enforcement discretion remains less durable than completed rulemaking and is vulnerable to reversal, agency leadership changes or safety signals. The contrarian read is that markets may capitalize a large addressable-market estimate as near-term earnings; the policy may instead unlock a narrow, operationally constrained product with asymmetric downside if safety or promotional concerns escalate. No company-specific margin, uptake or valuation data here supports treating this as a material earnings revision yet.

Key Decisions for Investors

• Do not chase HIMS on the policy headline alone. Reassess when the OMB review produces public text confirming covered compounds, duration, enforcement scope and any safeguards; an interim policy is not formal approval.
• Treat HIMS as a watchlist catalyst, not a standalone long thesis. Consider a small, defined-risk call spread only after HIMS confirms an in-scope product and a credible fulfillment/compliance plan; cap risk at premium paid and verify option liquidity and pricing before entry.
• Track HIMS disclosures for launch timing, repeat use, customer conversion and any compliance or adverse-event commentary. These are the missing indicators needed to judge whether the opportunity is material rather than promotional.
• Falsify the constructive view if the final policy excludes the compounds HIMS intends to offer, is delayed or reversed, or if safety events prompt renewed enforcement. A confirmed launch without evidence of customer uptake would also argue against assigning meaningful earnings value.